Novartis candidate vaccine Bexsero shows significant potential in providing broad coverage against meningococcal serogroup B infections
Pivotal study in more than 1,800 infants shows Bexsero induces robust immune response when given alone or with other routine vaccines in different vaccination schedules
15-Jun-2011 -
New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero® (Multicomponent Meningococcal Serogroup B Vaccine) induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines. These ...
bacterial meningitis
Bexsero
meningococcal disease
+2